This was recently posted on the 'other' board. It is well

New Post Public Reply Private Reply Replies (0) Message Board
WBeacham
385
This was recently posted on the 'other' board. It is well worth a detailed read. 

** ===== >>> I appreciate the attempt to upgrade the site (long overdue) but, as per usual, corporate crap overrules and dominates common sense. You mixed up 'Italic' w/ 'Quote'. What else is 'mixed up'? And pastel colors, in particular gray, looks like crap. You have an off-white background w/ pastel gray sans serif Helvetica as the standard font? ugh !!! Use actual colors, NOT pastels. Must everything be non-offensive and utterly bland ??? And what about Serif fonts ??? What, too offensive ?? With Helvetica, or other sans serif fonts, you can barely distinguish between an 'l', a 't', an 'i' or an 'r' making it difficult to read. Even the 'underline', you can barely see it. Trying to please, or not offend anyone, annoys and repulses every thinking adult in the room. Let the chips fall where they may. And where is the button to communicate directly w/ the site administrators ??? And finally, there is no separate window for 'previewing' your post while editing it. Good grief. ** just posted ... don't allow for blank lines ??? can't separate my closing lines from the body of the message. Is there anybody home ??? 

Hawk05  06 Mar 26 //  0544 hrs // Post #351,902  //

Voltaren, the leading topical NSAID gel for arthritis and muscle pain, maintains robust sales in key markets amid healthcare sector shifts, offering North American investors exposure to Haleon's consumer health powerhouse amid rising demand for non-opioid pain solutions.https://mdb.ad-hoc-news.de/bild/bild-2471716_1200_900.webpVoltaren stands as the world's top-selling topical diclofenac gel for fast-acting relief from arthritis pain, backaches, and sprains, with recent market expansions and sustained demand highlighting its commercial strength in a post-pandemic world favoring non-addictive pain management. - By Dr. Elena Marcus, Pharmaceutical Market Analyst: Voltaren's proven efficacy in the OTC pain relief segment positions it as a resilient asset in Haleon's portfolio, capitalizing on growing consumer preference for targeted topical treatments over systemic medications.

Voltaren, primarily known as a 1% diclofenac diethylamine gel, holds a commanding position in the over-the-counter (OTC) topical analgesic market globally. Its availability without prescription in North America since 2020 has driven significant uptake, particularly among consumers seeking alternatives to oral painkillers. The product's appeal lies in its targeted delivery, minimizing gastrointestinal side effects common with oral NSAIDs. Recent consumer health trends show a 15-20% year-over-year increase in topical pain relief sales, with Voltaren capturing over 40% market share in categories like osteoarthritis knee pain. In North America, where arthritis affects over 58 million adults, Voltaren's clinically proven 12-hour relief profile addresses a critical need. Investors note its stability amid volatile healthcare stocks, as consumer staples like pain gels weather economic fluctuations better than pharmaceuticals.

The official product page or announcement offers the most direct context for the latest development around Voltaren. https://www.voltaren.ch/Voltaren's  gel formulation uses diclofenac, a potent NSAID that penetrates the skin to reduce inflammation at the source. Unlike creams or patches, its clear, non-greasy gel dries quickly, enabling twice-daily application for sustained relief. Clinical trials demonstrate superior efficacy over placebos, with 70% of users reporting significant pain reduction within one hour. This data supports its recommendation by rheumatologists and pharmacists worldwide. Recent line extensions, such as Voltaren ActiPatch combining gel with wearable tech, expand its appeal to active lifestyles. These innovations sustain repeat purchases, boosting lifetime value per consumer. In competitive landscapes, Voltaren outperforms generics through brand trust built over decades. Its odorless, fragrance-free options cater to sensitive skin users, broadening accessibility. Originally developed by Novartis, Voltaren transitioned to Haleon following the 2022 GSK consumer health spin-off.

Haleon, now independent, manages Voltaren's global portfolio, with the CH-Lizenz (CH0012005267) representing Swiss licensing interests tied to historical Novartis/GSK ventures. In North America, Haleon markets Voltaren Max Strength 1.5% gel, approved by the FDA for broader indications . Sales exceed $500 million annually in the US alone , per industry estimates. Strategic manufacturing in Europe ensures supply chain resilience , even as geopolitical tensions rise. Haleon's focus on consumer health yields high margins, around 25-30% for top brands like Voltaren. Regulatory approvals in 50+ countries underscore its safety profile, with adverse events below 1% in post-market surveillance . This reliability attracts institutional investors seeking defensive plays. The ISIN CH0012005267 links to Voltaren's CH-Lizenz, providing indirect exposure to Haleon's performance via Swiss market structures. While Haleon trades primarily on London Stock Exchange (HLN), this instrument offers North American investors a euro-denominated alternative amid currency diversification needs. Haleon's Q1 2026 guidance projects 4-6% organic growth, driven by power-brands like Voltaren. Healthcare sector headwinds, with S&P 500 Health Care at 72% above 5-day averages but lagging YTD, position Voltaren as a bright spot. Dividend yields around 2.5% and buyback programs enhance shareholder returns.

North American funds tracking consumer staples indices increasingly allocate to Haleon for its 70% recurring revenue from OTC leaders. North America's opioid crisis has accelerated demand for non-addictive alternatives, with Voltaren filling the gap. CDC guidelines now prioritize topicals for mild-to-moderate pain, boosting prescription-to-OTC switches. Market data shows topical NSAIDs growing at 8% CAGR through 2030, outpacing oral segments. Voltaren's direct-to-consumer marketing, via TV and digital, reaches 100 million impressions yearly. E-commerce penetration, up 25% post-COVID, favors Voltaren's Amazon dominance. Partnerships with retailers like Walmart and CVS ensure shelf priority, sustaining velocity . For investors, this translates to resilient earnings amid inflation, as pricing power allows 3-5% annual hikes without volume loss. Haleon's scale negotiates favorable trade terms, protecting margins. Voltaren faces competition from Icy Hot, Biofreeze, and generic diclofenac, yet leads with 35% US market share . Its patented Max Strength formula deters copycats until 2028. Brand loyalty metrics show 60% repeat rate, versus 40% for newcomers. Haleon's R&D investment, $300 million annually, fuels next-gen formulations like nanotechnology-enhanced gels.

In Europe and Asia, Voltaren's presence in 90% of pharmacies creates moats. North American expansion via Haleon's Sensodyne synergies cross-sells to oral pain sufferers. SWOT analysis reveals strengths in efficacy and distribution, opportunities in aging populations, threats from regulatory scrutiny on NSAIDs, and weaknesses in higher price points. Looking to 2026-2030, Voltaren eyes pediatric and veterinary extensions, pending approvals. Sustainability initiatives, like recyclable tubes, align with ESG mandates attracting $40 trillion in assets. Digital health integrations, such as app-tracked dosing, enhance adherence. Haleon's M&A strategy may acquire complementary topicals, scaling Voltaren's ecosystem. North American investors benefit from Haleon's ADR availability (NYSE: HLN), simplifying access. Projections indicate 10% EPS growth, supported by Voltaren's 20% category outperformance. Risks include patent cliffs and supply disruptions, mitigated by diversified sourcing. Overall, Voltaren remains a cornerstone for long-term portfolios focused on health consumerism. 
"Sic parvis magna" -  GREATNESS  from small beginnings All the best, WBeacham

BioElectronics Corporation (BIEL) Stock Research Links

BIEL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI Echo Study Sharpens a Difficult HFpEF Diagnosis

Updated Category News Views 71

A single echo clip may be doing more useful work than plenty of flashy healthcare AI demos. The November 2026 Journal of Cardiac Failure focus issue puts a hard number on that possibility: pairing an AI read of a routine echocardiogram clip with the H?FPEF clinical score identified 78% of patients with hemodynamically confirmed HFpEF, versus 48% with the score alone. That...

Continue Reading
Grupo Supervielle's Q3 2026: Back to Growth Path

Updated Category News Views 89

Mounting Momentum in Loans and Asset Quality Grupo Supervielle, the Argentine financial player, has been tinkering with its gears to navigate the bumpy roads of 2026. In the third quarter, the company reports a gentle uptick in net loans—up 1.3% sequentially. This was particularly felt in September, with loans increasing 3.7%. Holding Their Own Against the Industry...

Continue Reading
MobileX's $10 Plan Puts Holiday Pressure on Wireless

Updated Category News Views 110

A sixty-dollar commitment is a small bet, but in wireless it can become a loud little nuisance for every carrier charging far more. MobileX has rolled out a Black Friday offer giving new customers 10GB of high-speed data, unlimited talk and text, and six months of service for $60 upfront. That pencils out to $10 a month, before taxes and government surcharges, and it runs...

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 77

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 226

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 59

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector

Updated Category News Views 112

Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...

Continue Reading
LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 66

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 115

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 207

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading

Top 5 Most Recently Viewed Articles

Feeding America Urges Collaboration to Combat Hunger Crisis

Updated Category News Views 148

Feeding America's Call to Action Against Hunger As food insecurity continues to rise, people across the nation who are struggling with hunger are urging us to unite and take meaningful steps to tackle this critical issue. Recent data indicates a troubling 6% increase in food insecurity over the past year, highlighting the immediate need for a collective response. Even...

Continue Reading
Aviat Networks Announces Participation in Key Investor Events

Updated Category News Views 136

Exciting Investor Conferences Ahead for Aviat Networks Aviat Networks, Inc. (NASDAQ: AVNW), a prominent player in the realm of wireless transport and access solutions, has recently unveiled its participation in some significant upcoming investor conferences. These conferences are an excellent opportunity for investors to engage with the company and learn more about its...

Continue Reading
Berkshire Hathaway Secures $1.9B with Major Samurai Bond Sale

Updated Category News Views 277

Berkshire Hathaway's Significant Samurai Bond Offering Berkshire Hathaway (NYSE: BRK) has successfully concluded a major bond offering, securing 281.8 billion yen, which is approximately $1.9 billion. This achievement marks the company's largest Samurai bond sale in five years, reflecting its strategic intent to deepen its investment footprint in the Japanese market. The...

Continue Reading
Top 10 Trading Mistakes to Avoid for Successful Investing

Updated Category News Views 150

The Costly Errors in Trading Many traders stumble not due to a lack of opportunities, but because they inadvertently make damaging decisions. It's crucial to recognize that the line between success and failure often lies in avoiding habits that negatively impact your trading account. In this article, we will delve into the 10 most detrimental trading mistakes....

Continue Reading
DEWALT POWERSHIFT™: Revolutionizing Electric Tools for Future Jobsites

Updated Category News Views 344

DEWALT POWERSHIFT™: A Leap Towards Sustainability DEWALT, a distinguished name in construction tools, has just introduced the DEWALT POWERSHIFT™ Cordless Equipment System, a groundbreaking series of tools designed to transform the future of jobsites. This innovative system significantly reduces environmental impact, boasting a remarkable capability to produce up to...

Continue Reading